OncoMatch/Clinical Trials/NCT05642455

SPEARHEAD-3 Pediatric Study

Is NCT05642455 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for synovial sarcoma.

Phase 1/2RecruitingUSWM CT, LLCNCT05642455Data as of May 2026

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Neuroblastoma

Osteosarcoma

Biomarker criteria

Required: HLA-A A*02 positive

HLA-A*02 positive

Required: MAGEA4 expression

Tumor shows MAGE-A4 expression confirmed by central laboratory.

Excluded: HLA-A A*02:05 positive

Positive for HLA-A*02:05 in either allele; or any A*02 having same protein sequence as HLA-A*02:05

Prior therapy

Min 1 prior line

Must have received: systemic chemotherapy

Must have previously received a systemic chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

National Institutes of Health · Bethesda, Maryland
Dana Farber Cancer Institute · Boston, Massachusetts
Washington University · St Louis, Missouri
Memorial Sloan Kettering Kids · New York, New York
Duke University School of Medicine · Durham, North Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify